{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biomarker+blood+draw&page=11", "query": { "intervention": "Biomarker blood draw", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 1741, "total_pages": 175, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biomarker+blood+draw&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biomarker+blood+draw&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T08:00:13.492Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01996527", "title": "3T MRI Biomarkers of Glioma Treatment Response", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Ependymoma", "Adult Anaplastic Oligodendroglioma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Tumor" ], "interventions": [ { "name": "3-Tesla magnetic resonance imaging", "type": "DEVICE" }, { "name": "CEST-MRI", "type": "DEVICE" }, { "name": "DW-MRI", "type": "DEVICE" }, { "name": "DCE-MRI", "type": "DEVICE" }, { "name": "DSC-MRI", "type": "DEVICE" }, { "name": "IV administration of gadolinium-containing contrast agent", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2012-05", "completion_date": "2016-01-01", "has_results": false, "last_update_posted_date": "2017-04-17", "last_synced_at": "2026-10-12T08:00:13.492Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01996527" }, { "nct_id": "NCT02069613", "title": "Multimodal Approach to Testing the Acute Effects of Mild Traumatic Brain Injury (mTBI)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Concussion, Mild" ], "interventions": [], "intervention_types": [], "sponsor": "Huntington Medical Research Institutes", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 44, "start_date": "2014-03", "completion_date": "2017-08-01", "has_results": false, "last_update_posted_date": "2017-11-08", "last_synced_at": "2026-10-12T08:00:13.492Z", "location_count": 3, "location_summary": "Pasadena, California", "locations": [ { "city": "Pasadena", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02069613" }, { "nct_id": "NCT06213883", "title": "Response to Acute Exercise in Eating Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Eating Disorders" ], "interventions": [ { "name": "Biobehavioral Response to in-lab exposure to physical activity", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": "25 Years", "sex": "FEMALE", "summary": "16 Years to 25 Years · Female only" }, "enrollment_count": 74, "start_date": "2023-11-02", "completion_date": "2025-07-31", "has_results": true, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-12T08:00:13.492Z", "location_count": 2, "location_summary": "San Francisco, California • Madison, Wisconsin", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06213883" }, { "nct_id": "NCT00061945", "title": "Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Undifferentiated Leukemia", "B-cell Adult Acute Lymphoblastic Leukemia", "B-cell Childhood Acute Lymphoblastic Leukemia", "L1 Adult Acute Lymphoblastic Leukemia", "L1 Childhood Acute Lymphoblastic Leukemia", "L2 Adult Acute Lymphoblastic Leukemia", "L2 Childhood Acute Lymphoblastic Leukemia", "Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia", "Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia", "Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia", "T-cell Adult Acute Lymphoblastic Leukemia", "T-cell Childhood Acute Lymphoblastic Leukemia", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Childhood Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "allopurinol", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "asparaginase", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "trimethoprim-sulfamethoxazole", "type": "DRUG" }, { "name": "mercaptopurine", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "alemtuzumab", "type": "BIOLOGICAL" }, { "name": "acyclovir", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 302, "start_date": "2003-06", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2022-05-03", "last_synced_at": "2026-10-12T08:00:13.492Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00061945" }, { "nct_id": "NCT00989651", "title": "Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fallopian Tube Carcinoma", "Fallopian Tube Carcinosarcoma", "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Neoplasm", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Ovarian Brenner Tumor", "Ovarian Carcinoma", "Ovarian Carcinosarcoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Seromucinous Tumor", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Primary Peritoneal Carcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Stage IIA Fallopian Tube Cancer AJCC v6 and v7", "Stage IIA Ovarian Cancer AJCC V6 and v7", "Stage IIB Fallopian Tube Cancer AJCC v6 and v7", "Stage IIB Ovarian Cancer AJCC v6 and v7", "Stage IIC Fallopian Tube Cancer AJCC v6 and v7", "Stage IIC Ovarian Cancer AJCC v6 and v7", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 431, "start_date": "2009-10-28", "completion_date": "2020-04-10", "has_results": false, "last_update_posted_date": "2021-10-20", "last_synced_at": "2026-10-12T08:00:13.492Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Augusta, Georgia + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00989651" }, { "nct_id": "NCT01009437", "title": "Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "ritonavir", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 28, "start_date": "2010-05-26", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-10-12T08:00:13.492Z", "location_count": 2, "location_summary": "Minneapolis, Minnesota • Philadelphia, Pennsylvania", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01009437" }, { "nct_id": "NCT00550537", "title": "Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "proteomic profiling", "type": "GENETIC" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 116, "start_date": "2007-10", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2017-06-08", "last_synced_at": "2026-10-12T08:00:13.492Z", "location_count": 7, "location_summary": "Gainesville, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00550537" }, { "nct_id": "NCT02532231", "title": "Nivolumab in AML in Remission at High Risk for Relapse", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Adult Acute Myeloid Leukemia in Remission", "Blasts Under 10 Percent of Bone Marrow Nucleated Cells", "Therapy-Related Myeloid Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2015-10-19", "completion_date": "2023-08-08", "has_results": true, "last_update_posted_date": "2024-10-24", "last_synced_at": "2026-10-12T08:00:13.492Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02532231" }, { "nct_id": "NCT01746836", "title": "Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Ponatinib Hydrochloride", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2013-01-17", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-12T08:00:13.492Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01746836" }, { "nct_id": "NCT00048971", "title": "Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer", "Diarrhea", "Neutropenia" ], "interventions": [ { "name": "mutation analysis", "type": "GENETIC" }, { "name": "polymorphic microsatellite marker analysis", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 308, "start_date": "2002-04", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2016-07-06", "last_synced_at": "2026-10-12T08:00:13.492Z", "location_count": 82, "location_summary": "Anniston, Alabama • La Jolla, California • Los Angeles, California + 58 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00048971" } ] }